{"id":"high-dose-of-unfractionated-heparin","safety":{"commonSideEffects":[{"rate":"5-10","effect":"Bleeding"},{"rate":"1-3","effect":"Thrombocytopenia"},{"rate":"0.5-2","effect":"Heparin-induced thrombocytopenia (HIT)"},{"rate":null,"effect":"Osteoporosis (with prolonged use)"},{"rate":null,"effect":"Hyperkalemia"}]},"_chembl":{"chemblId":"CHEMBL1159488","moleculeType":"Small molecule","molecularWeight":"711.47"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Unfractionated heparin (UFH) is a naturally occurring glycosaminoglycan that binds to antithrombin III and dramatically accelerates its inhibition of thrombin (Factor IIa) and Factor Xa. At high doses, UFH provides rapid anticoagulation suitable for acute thrombotic events and is commonly used in hospital settings for conditions requiring immediate anticoagulation. The high-dose formulation achieves therapeutic anticoagulation quickly, making it suitable for acute coronary syndromes, pulmonary embolism, and deep vein thrombosis.","oneSentence":"High-dose unfractionated heparin inhibits blood coagulation by potentiating antithrombin III, which inactivates thrombin and other clotting factors.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:22:16.434Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Acute coronary syndrome"},{"name":"Pulmonary embolism"},{"name":"Deep vein thrombosis"},{"name":"Acute thrombosis prevention"}]},"trialDetails":[{"nctId":"NCT07497165","phase":"","title":"Epunamin Combined With DECP for Relapsed/Refractory Multiple Myeloma","status":"RECRUITING","sponsor":"Shanxi Bethune Hospital","startDate":"2025-11-01","conditions":"Relapsed/Refractory Multiple Myeloma (RRMM), Multiple Myeloma","enrollment":48},{"nctId":"NCT07299695","phase":"PHASE3","title":"Intravenous Immunoglobulin for the Treatment of Acute Exacerbations of Idiopathic Pulmonary Fibrosis","status":"RECRUITING","sponsor":"Argyrios Tzouvelekis","startDate":"2026-01-25","conditions":"Idiopathic Pulmonary Fibrosis, Acute Exacerbation of Idiopathic Pulmonary Fibrosis","enrollment":196},{"nctId":"NCT07288489","phase":"PHASE3","title":"Phase 3 Trial of VMX-C001 vs Usual Pharmacological Care in Patients Taking a FXa Direct Oral Anticoagulant Who Require Urgent Surgery With or Without Heparin.","status":"NOT_YET_RECRUITING","sponsor":"VarmX B.V.","startDate":"2026-03","conditions":"Blood Loss, Surgical, Coagulation Disorder","enrollment":800},{"nctId":"NCT04374799","phase":"PHASE3","title":"Heparin vs Placebo for Cardiac Catheterization","status":"RECRUITING","sponsor":"London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's","startDate":"2020-10-05","conditions":"Cardiac Disease","enrollment":1623},{"nctId":"NCT06313203","phase":"PHASE2","title":"HAI-Floxuridine, or SIRT, Combined With Gemox For Patients With Intra-Hepatic Cholangiocarcinoma Not Amenable to Resection (TOMCAT)","status":"RECRUITING","sponsor":"Oslo University Hospital","startDate":"2024-02-13","conditions":"Intrahepatic Cholangiocarcinoma, Chemotherapy Effect","enrollment":39},{"nctId":"NCT06096116","phase":"PHASE3","title":"Phase 3 Study on the Efficacy and Safety of Human Plasma Derived Antithrombin (Atenativ) in Heparin-Resistant Patients Scheduled to Undergo Cardiac Surgery Necessitating Cardiopulmonary Bypass","status":"RECRUITING","sponsor":"Octapharma","startDate":"2024-08-21","conditions":"Acquired Antithrombin Deficiency","enrollment":120},{"nctId":"NCT07361679","phase":"PHASE4","title":"LDA and LMWH vs LDA Alone in High-risk Patients for Preeclampsia Prevention","status":"RECRUITING","sponsor":"Alexandra Hospital, Athens, Greece","startDate":"2023-01-18","conditions":"Preeclampsia Severe, Toxemia Of Pregnancy, Preeclampsia","enrollment":100},{"nctId":"NCT07140523","phase":"PHASE2","title":"A Study to Compare the Efficacy and Safety of SRSD107 and Enoxaparin in Adult Subjects Undergoing TKA","status":"RECRUITING","sponsor":"Sirius Therapeutics Co., Ltd.","startDate":"2025-09-16","conditions":"Venous Thromboembolism","enrollment":450},{"nctId":"NCT05255003","phase":"PHASE4","title":"STrategies for Anticoagulation in Patients With thRombocytopenia and Cancer-associated Thrombosis","status":"RECRUITING","sponsor":"Tzu-Fei Wang","startDate":"2022-08-29","conditions":"Cancer-associated Thrombosis, Thrombocytopenia","enrollment":50},{"nctId":"NCT07285603","phase":"PHASE1","title":"A Study in Healthy Subjects to Assess the Safety and Tolerability of a 120-hour Continuous Infusion of M6229","status":"COMPLETED","sponsor":"Matisse Pharmaceuticals","startDate":"2024-11-21","conditions":"Healthy Subjects","enrollment":15},{"nctId":"NCT06329921","phase":"NA","title":"Inpatient Monitoring of Unfractionated Heparin","status":"ENROLLING_BY_INVITATION","sponsor":"Vanderbilt University Medical Center","startDate":"2024-06-26","conditions":"Blood Clot, Thrombosis","enrollment":2000},{"nctId":"NCT07214103","phase":"PHASE2","title":"Phase IIb Multicenter Randomized Controlled Trial Evaluating the Efficacy of Sivelestat in Patients With Septic Coagulopathy","status":"NOT_YET_RECRUITING","sponsor":"University Hospital, Strasbourg, France","startDate":"2026-03-01","conditions":"Septic Shock, Coagulopathy","enrollment":120},{"nctId":"NCT04049591","phase":"NA","title":"Higher vs. Lower Dose Heparin for PCI","status":"RECRUITING","sponsor":"Population Health Research Institute","startDate":"2022-03-02","conditions":"Cardiovascular Diseases, Percutaneous Coronary Intervention","enrollment":16000},{"nctId":"NCT04924322","phase":"PHASE2, PHASE3","title":"Catheter-Related Early Thromboprophylaxis With Enoxaparin Studies","status":"RECRUITING","sponsor":"Yale University","startDate":"2022-05-11","conditions":"Deep Venous Thrombosis","enrollment":258},{"nctId":"NCT06861374","phase":"NA","title":"Bivalirudin with Prolonged Infusion During PCI Versus Heparin After Fibrinolytic Therapy","status":"NOT_YET_RECRUITING","sponsor":"First Affiliated Hospital Xi'an Jiaotong University","startDate":"2025-05","conditions":"ST-segment Elevation Myocardial Infarction (STEMI)","enrollment":2400},{"nctId":"NCT06833827","phase":"NA","title":"'Thrombectomy in High-Risk Pulmonary Embolism - Device Versus Thrombolysis Netherlands': TORPEDO-NL","status":"RECRUITING","sponsor":"Leiden University Medical Center","startDate":"2025-02","conditions":"Pulmonary Embolism Acute","enrollment":111},{"nctId":"NCT04061798","phase":"PHASE4","title":"ACT Guided Heparinization During Open Abdominal Aortic Aneurysm Repair.","status":"TERMINATED","sponsor":"Dijklander Ziekenhuis","startDate":"2020-03-02","conditions":"Abdominal Aortic Aneurysm, Surgery, Arterial Disease","enrollment":294},{"nctId":"NCT04362085","phase":"PHASE3","title":"Coagulopathy of COVID-19: A Pragmatic Randomized Controlled Trial of Therapeutic Anticoagulation Versus Standard Care","status":"COMPLETED","sponsor":"Unity Health Toronto","startDate":"2020-05-11","conditions":"COVID-19","enrollment":465},{"nctId":"NCT04507178","phase":"PHASE2","title":"Improving Outcome in Subarachnoid Hemorrhage wIth Nadroparine","status":"RECRUITING","sponsor":"Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)","startDate":"2022-02-02","conditions":"Aneurysmal Subarachnoid Hemorrhage, Delayed Cerebral Ischemia","enrollment":100},{"nctId":"NCT04710732","phase":"PHASE4","title":"Individual Dose Adjustment of Low-molecular-weight-heparin by Thromodynamics Test.","status":"TERMINATED","sponsor":"Pirogov Russian National Research Medical University","startDate":"2021-03-01","conditions":"Venous Thromboembolism","enrollment":9},{"nctId":"NCT06693362","phase":"PHASE1","title":"A Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Study to Evaluate the Safety and Efficacy of Uterine Blood Mesenchymal Stem Cells Injection for the Treatment of Severe Pneumonia Caused by Viruses","status":"RECRUITING","sponsor":"Ruijin Hospital","startDate":"2025-01-20","conditions":"Severe Viral Pneumonia(Not Include COVID-19)","enrollment":60},{"nctId":"NCT06707389","phase":"EARLY_PHASE1","title":"Autologous Blood Monocyte Vesicles for the Treatment of Sudden Deafness","status":"NOT_YET_RECRUITING","sponsor":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","startDate":"2024-12-25","conditions":"Sudden Deafness, Sensorineural Hearing Loss","enrollment":30},{"nctId":"NCT03152058","phase":"PHASE2","title":"IMPACT Study: IMProve Pregnancy in APS With Certolizumab Therapy","status":"RECRUITING","sponsor":"David Ware Branch","startDate":"2017-05-17","conditions":"High Risk Pregnancy, Pregnancy Complications, Antiphospholipid Syndrome in Pregnancy","enrollment":55},{"nctId":"NCT04088292","phase":"PHASE3","title":"Low Dose Thrombolysis, Ultrasound Assisted Thrombolysis or Heparin for Intermediate High Risk Pulmonary Embolism","status":"ACTIVE_NOT_RECRUITING","sponsor":"Rigshospitalet, Denmark","startDate":"2019-06-06","conditions":"Pulmonary Embolism","enrollment":210},{"nctId":"NCT06646328","phase":"PHASE4","title":"Oxidative Stress and Circulating Nuclear DNA (cfDNA) in Acute Kidney Injury and Continuous Renal Replacement Therapies.","status":"TERMINATED","sponsor":"Fernando Sanchez","startDate":"2018-06-09","conditions":"Acute Kidney Injury","enrollment":20},{"nctId":"NCT04743011","phase":"PHASE1, PHASE2","title":"Enriched Heparin Anti COVID-19 Trial","status":"COMPLETED","sponsor":"UPECLIN HC FM Botucatu Unesp","startDate":"2021-06-01","conditions":"Covid19","enrollment":27},{"nctId":"NCT03853005","phase":"NA","title":"Effect of High volumeHemodiafiltration on Lung Oxygenation","status":"COMPLETED","sponsor":"Assiut University","startDate":"2019-03-20","conditions":"Haemofiltration, Lung Mechanics, Septic Patients","enrollment":40},{"nctId":"NCT05122780","phase":"PHASE4","title":"Prognostic Value of Precision Medicine in Patients With MINOCA (PROMISE Trial).","status":"ACTIVE_NOT_RECRUITING","sponsor":"Fondazione Policlinico Universitario Agostino Gemelli IRCCS","startDate":"2021-07-01","conditions":"Myocardial Infarction With Non-Obstructive Coronary Arteries","enrollment":120},{"nctId":"NCT02735707","phase":"PHASE3","title":"Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia","status":"RECRUITING","sponsor":"UMC Utrecht","startDate":"2016-04-11","conditions":"Community-acquired Pneumonia, Influenza, COVID-19","enrollment":20000},{"nctId":"NCT06487052","phase":"NA","title":"Evaluation of the Standard Catheter-directed Thrombolysis Effectiveness in Intermediate-High-Risk Pulmonary Embolism Patients","status":"RECRUITING","sponsor":"Federal State Budgetary Institution, V. A. Almazov Federal North-West Medical Research Centre, of the Ministry of Health","startDate":"2024-01-10","conditions":"Pulmonary Embolism Acute","enrollment":100},{"nctId":"NCT06153394","phase":"PHASE3","title":"Prolonged Hypercoagulability Following Major Liver Resection for Malignancy","status":"NOT_YET_RECRUITING","sponsor":"Western University, Canada","startDate":"2024-06-01","conditions":"Hepatic Disease, Surgery-Complications, Hypercoagulability","enrollment":50},{"nctId":"NCT03659708","phase":"NA","title":"Pregnancy and Risk of Venous Thromboembolism","status":"RECRUITING","sponsor":"Hospices Civils de Lyon","startDate":"2021-01-22","conditions":"Thromboembolism, Pregnancy","enrollment":600},{"nctId":"NCT04561648","phase":"NA","title":"Standard vs High Dose of Unfractionated Heparin in the Incidence of Radial Artery Occlusion (DEFINITION) Trial.","status":"UNKNOWN","sponsor":"Instituto Nacional de Cardiologia Ignacio Chavez","startDate":"2020-08-01","conditions":"Radial Artery Occlusion","enrollment":1988},{"nctId":"NCT05749393","phase":"NA","title":"Effect of Different Heparinization Schemes on Prognosis of Intracranial Aneurysm","status":"UNKNOWN","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2023-04-30","conditions":"Intracranial Aneurysm","enrollment":90},{"nctId":"NCT04536363","phase":"PHASE2","title":"Cri Analog PG1 Effectiveness and Safety in Covid-19","status":"WITHDRAWN","sponsor":"Alonso Vera Torres","startDate":"2020-12-03","conditions":"Covid19","enrollment":""},{"nctId":"NCT04593654","phase":"","title":"Dosing of Thromboprophylaxis and Mortality in Critically Ill COVID-19 Patients","status":"COMPLETED","sponsor":"Karolinska Institutet","startDate":"2020-03-01","conditions":"Covid19, Thromboembolism","enrollment":257},{"nctId":"NCT04542408","phase":"PHASE3","title":"Hamburg Edoxaban for Anticoagulation in COVID-19 Study","status":"COMPLETED","sponsor":"Universitätsklinikum Hamburg-Eppendorf","startDate":"2020-11-12","conditions":"Covid19","enrollment":140},{"nctId":"NCT05178550","phase":"EARLY_PHASE1","title":"A Study in Healthy Participants Investigating Biomarkers After Exposure to Heparin When Heparin is Administered in the Fasted State or After a High-fat Meal. Heparin, a Registered Drug, is an Anticoagulant (Blood Thinner) That Prevents the Formation of Blood Clots.","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2021-12-17","conditions":"Healthy Volunteers","enrollment":12},{"nctId":"NCT04655586","phase":"PHASE2, PHASE3","title":"Assessing Safety, Hospitalization and Efficacy of rNAPc2 in COVID-19","status":"COMPLETED","sponsor":"ARCA Biopharma, Inc.","startDate":"2020-12-10","conditions":"Covid19","enrollment":160},{"nctId":"NCT04569279","phase":"PHASE3","title":"Rivaroxaban vs. Warfarin in CVT Treatment","status":"COMPLETED","sponsor":"Damascus University","startDate":"2017-09-01","conditions":"Cerebral Vein Thrombosis","enrollment":71},{"nctId":"NCT05493163","phase":"PHASE4","title":"Catheter-directed Thrombolysis in Intermediate-high Risk Acute Pulmonary Embolism","status":"RECRUITING","sponsor":"Faculty Hospital Kralovske Vinohrady","startDate":"2022-10-19","conditions":"Pulmonary Embolism","enrollment":558},{"nctId":"NCT05591872","phase":"PHASE3","title":"Low Dose Heparin Factorial Trial","status":"UNKNOWN","sponsor":"Tabba Heart Institute","startDate":"2022-05-09","conditions":"Radial Artery Occlusion","enrollment":800},{"nctId":"NCT03145675","phase":"PHASE4","title":"Optimizing the Anticoagulation Regimen of Enoxaparin During Percutaneous Coronary Intervention (OPTIENOX-PCI)","status":"COMPLETED","sponsor":"Peking Union Medical College Hospital","startDate":"2017-05-12","conditions":"Coronary Artery Disease, Percutaneous Coronary Intervention","enrollment":378},{"nctId":"NCT03812848","phase":"NA","title":"Clinical Pharmacist-led Inpatient Anticoagulation Stewardship Program","status":"COMPLETED","sponsor":"Ain Shams University","startDate":"2018-01-01","conditions":"Deep Vein Thrombosis, Atrial Fibrillation, Mitral Valve Disease","enrollment":233},{"nctId":"NCT04730856","phase":"NA","title":"Standard vs High Prophylactic Doses or Anticoagulation in Patients With High Risk of Thrombosis Admitted With COVID-19 Pneumonia (PROTHROMCOVID)","status":"COMPLETED","sponsor":"Hospital Universitario Infanta Leonor","startDate":"2021-02-01","conditions":"Covid19, Thrombosis","enrollment":311},{"nctId":"NCT04808882","phase":"PHASE2","title":"ANTIcoagulation in Severe COVID-19 Patients","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2021-04-14","conditions":"Severe COVID-19 Pneumonia","enrollment":353},{"nctId":"NCT05512702","phase":"","title":"Reduced Dose Thrombolytic in Intermediate/High Risk Pulmonary Thromboembolism","status":"UNKNOWN","sponsor":"Ege University","startDate":"2022-06-03","conditions":"Pulmonary Embolism","enrollment":100},{"nctId":"NCT04110444","phase":"","title":"Sildenafil Citrate Added to Low Molecular Weight Heparin and Low Dose Aspirin in High-risk Pregnancy","status":"WITHDRAWN","sponsor":"Fayoum University Hospital","startDate":"2017-01","conditions":"High Risk Pregnancy","enrollment":""},{"nctId":"NCT04623177","phase":"","title":"Thromboprophylaxis for Patients in ICU With COVID-19","status":"COMPLETED","sponsor":"Instituto de Investigacion Sanitaria La Fe","startDate":"2020-03-01","conditions":"Covid19, Anticoagulant Therapy, Thrombosis","enrollment":822},{"nctId":"NCT04377997","phase":"PHASE2","title":"Safety and Efficacy of Therapeutic Anticoagulation on Clinical Outcomes in Hospitalized Patients With COVID-19","status":"UNKNOWN","sponsor":"Massachusetts General Hospital","startDate":"2020-05-15","conditions":"Cardiovascular Diseases, COVID-19","enrollment":300},{"nctId":"NCT05172115","phase":"PHASE3","title":"Catheter-Directed Thrombolysis Versus Anticoagulation Monotherapy in Intermediate-High Risk PE","status":"TERMINATED","sponsor":"Rajaie Cardiovascular Medical and Research Center","startDate":"2018-12-22","conditions":"Pulmonary Embolism, Pulmonary Thromboembolisms, Embolism, Pulmonary","enrollment":94},{"nctId":"NCT01161641","phase":"PHASE1","title":"Pilot/Ph I Safety and Efficacy of ODSH in Protein Losing Enteropathy Secondary to Single Ventricle Palliative Surgery","status":"TERMINATED","sponsor":"Jazz Pharmaceuticals","startDate":"2010-07","conditions":"Protein Losing Enteropathy","enrollment":5},{"nctId":"NCT04401293","phase":"PHASE3","title":"Full Dose Heparin Vs. Prophylactic Or Intermediate Dose Heparin in High Risk COVID-19 Patients","status":"COMPLETED","sponsor":"Northwell Health","startDate":"2020-04-26","conditions":"Sars-CoV2, COVID","enrollment":257},{"nctId":"NCT04444700","phase":"PHASE3","title":"A Pragmatic Randomized Controlled Trial of Therapeutic Anticoagulation Versus Standard Care as a Rapid Response to (SARS-CoV-2) COVID-19 Pandemic","status":"COMPLETED","sponsor":"University of Sao Paulo General Hospital","startDate":"2020-07-04","conditions":"COVID, Coronavirus Infection, Severe Acute Respiratory Syndrome","enrollment":465},{"nctId":"NCT02412982","phase":"PHASE4","title":"Evaluation of Venous Thromboembolism Prevention in High-Risk Trauma Patients","status":"COMPLETED","sponsor":"University of Cincinnati","startDate":"2016-03","conditions":"Traumatic Injury, Venous Thromboembolism","enrollment":103},{"nctId":"NCT04345848","phase":"PHASE3","title":"Preventing COVID-19 Complications With Low- and High-dose Anticoagulation","status":"TERMINATED","sponsor":"University Hospital, Geneva","startDate":"2020-04-28","conditions":"COVID, Sars-CoV2","enrollment":160},{"nctId":"NCT04158973","phase":"NA","title":"CHIPs-VTE Study in Hospitalized Patients With Lung Cancer","status":"UNKNOWN","sponsor":"China-Japan Friendship Hospital","startDate":"2021-12-01","conditions":"Venous Thromboembolic Disease, Pulmonary Embolism, Deep Venous Thrombosis","enrollment":3200},{"nctId":"NCT04511793","phase":"NA","title":"Hepatic Artery Infusion (HAI) Program at Duke University","status":"WITHDRAWN","sponsor":"Michael Lidsky, M.D.","startDate":"2020-12-11","conditions":"Metastatic Colon Cancer, Liver Cancer, Intrahepatic Cholangiocarcinoma","enrollment":""},{"nctId":"NCT02706249","phase":"PHASE2","title":"Study Of Weight-Based Versus Standard Dose Enoxaparin Thromboprophylaxis In High-Risk Hospitalized Cancer Patients","status":"COMPLETED","sponsor":"Dana-Farber Cancer Institute","startDate":"2016-04","conditions":"Venous Thormboembolism","enrollment":50},{"nctId":"NCT01522417","phase":"PHASE2","title":"Shortened Aggrastat® Versus Integrilin in Percutaneous Coronary Intervention","status":"COMPLETED","sponsor":"Medicure","startDate":"2012-04","conditions":"Myocardial Infarction, Acute Coronary Syndromes, Unstable Angina","enrollment":535},{"nctId":"NCT03854266","phase":"PHASE2","title":"Low Dose Catheter Directed Thrombolysis for Acute Pulmonary Embolism","status":"UNKNOWN","sponsor":"University of Aarhus","startDate":"2020-03-10","conditions":"Pulmonary Embolism","enrollment":60},{"nctId":"NCT02600260","phase":"NA","title":"Thromboprophylaxis in Pregnant Women in Hospital: A Prospective Clinical Trial","status":"COMPLETED","sponsor":"University of Sao Paulo General Hospital","startDate":"2014-12-01","conditions":"Thrombophilia Associated With Pregnancy, Perioperative/Postoperative Complications, Venous Thrombosis","enrollment":7212},{"nctId":"NCT04829552","phase":"","title":"Prophylactic Versus Therapeutic Dose Anticoagulation In COVID-19 Infection at the Time of Admission To Critical Care Units","status":"COMPLETED","sponsor":"Corewell Health East","startDate":"2020-03-10","conditions":"Covid19","enrollment":704},{"nctId":"NCT04778917","phase":"PHASE4","title":"Observation and Treatment of Pulmonary Microthrombosis in Childhood Pneumonia With Elevated D-dimer","status":"COMPLETED","sponsor":"Capital Institute of Pediatrics, China","startDate":"2014-12","conditions":"Pneumonia","enrollment":124},{"nctId":"NCT02618837","phase":"PHASE4","title":"Downstream Versus Upstream Strategy for the Administration of P2Y12 Receptor Blockers","status":"UNKNOWN","sponsor":"University of Padova","startDate":"2015-12-14","conditions":"Unstable Angina or Non ST Elevated Myocardial Infarction","enrollment":2520},{"nctId":"NCT01346098","phase":"PHASE2","title":"Islet Autotransplantation in Patients at Very High-risk Pancreatic Anastomosis","status":"COMPLETED","sponsor":"Ospedale San Raffaele","startDate":"2010-07","conditions":"Postpancreatectomy Hyperglycemia","enrollment":60},{"nctId":"NCT04520620","phase":"PHASE4","title":"Concentration-effect Relationship of Enoxaparin for Thromboembolic Prevention","status":"WITHDRAWN","sponsor":"Centre Hospitalier Universitaire de Saint Etienne","startDate":"2020-05-02","conditions":"Sars-CoV2","enrollment":""},{"nctId":"NCT01763606","phase":"NA","title":"Enoxaparin Versus Aspirin in Patients With Cancer and Stroke","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2012-12-18","conditions":"Cancer Patients First-ever Acute Ischemic Stroke","enrollment":20},{"nctId":"NCT00970619","phase":"PHASE3","title":"DUTCH CAVA-trial: CAtheter Versus Anticoagulation Alone for Acute Primary (Ilio)Femoral DVT.","status":"COMPLETED","sponsor":"Maastricht University Medical Center","startDate":"2010-05","conditions":"Acute Thrombosis of Deep Veins of Proximal Lower Extremity","enrollment":184},{"nctId":"NCT04241380","phase":"NA","title":"Anticoagulation Medicine in Surgical Repair for Total Anomalous Pulmonary Venous Connection","status":"UNKNOWN","sponsor":"Guangdong Provincial People's Hospital","startDate":"2020-02-20","conditions":"Total Anomalous Pulmonary Venous Connection","enrollment":150},{"nctId":"NCT04195997","phase":"PHASE4","title":"Multi-center Application of Bivalirudin in Left Atrial Appendage Occlusion","status":"UNKNOWN","sponsor":"Shanghai Zhongshan Hospital","startDate":"2020-02-01","conditions":"Evaluate the Safety and Efficacy of Bivalirudin in Decreasing Bleeding Risk","enrollment":100},{"nctId":"NCT03805672","phase":"PHASE4","title":"Below Knee DVT Study","status":"TERMINATED","sponsor":"Oregon Health and Science University","startDate":"2014-09","conditions":"Deep Vein Thrombosis (DVT), Blood Clots","enrollment":4},{"nctId":"NCT01433705","phase":"PHASE1","title":"Distribution of Rubidium-82, Nitrogen-13 Ammonia, and Fluorine-18 Fluorodeoxyglucose in Normal Volunteers","status":"COMPLETED","sponsor":"University of Michigan","startDate":"2011-11","conditions":"Heart Disease","enrollment":70},{"nctId":"NCT03140631","phase":"PHASE4","title":"Use of Protamine for Heparin Reversal After Catheter Ablation of Atrial Fibrillation","status":"COMPLETED","sponsor":"University of Michigan","startDate":"2017-03-23","conditions":"Atrial Fibrillation, Catheter Ablation","enrollment":153},{"nctId":"NCT02767232","phase":"PHASE3","title":"Pediatric High-Risk Deep Venous Thrombosis Lytic Outcomes Trial","status":"WITHDRAWN","sponsor":"University of Colorado, Denver","startDate":"2018-07","conditions":"Deep Vein Thrombosis, Post-Thrombotic Syndrome, Venous Thrombosis","enrollment":""},{"nctId":"NCT01520454","phase":"NA","title":"Effect of Increased Free Fatty Acids on Leptin Function","status":"COMPLETED","sponsor":"Beth Israel Deaconess Medical Center","startDate":"2011-11","conditions":"Obesity, Leptin Resistance","enrollment":26},{"nctId":"NCT02979158","phase":"NA","title":"Preoperative Dual Antiplatelet Therapy: Platelet Function and Influence of Cardiopulmonary Bypass","status":"COMPLETED","sponsor":"Umeå University","startDate":"2016-11","conditions":"Cardiopulmonary Bypass, Platelet Disorder, Bleeding Disorder","enrollment":60},{"nctId":"NCT02570243","phase":"PHASE4","title":"High (100IU/Kg) Versus Standard (50IU/Kg) Heparin Dose for Prevention of Forearm Artery Occlusion","status":"COMPLETED","sponsor":"University of Patras","startDate":"2015-02","conditions":"Coronary Angiography","enrollment":1800},{"nctId":"NCT00721136","phase":"NA","title":"Randomized Study of the Use of Warfarin During Pacemaker or ICD Implantation in Patients Requiring Long Term Anticoagulation","status":"COMPLETED","sponsor":"Johns Hopkins University","startDate":"2007-09","conditions":"Bradycardia, Tachycardia, Atrial Fibrillation","enrollment":104},{"nctId":"NCT00790907","phase":"PHASE4","title":"Fondaparinux Trial With Unfractionated Heparin (UFH) During Revascularization in Acute Coronary Syndromes (ACS)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2009-02","conditions":"Acute Coronary Syndrome","enrollment":3235},{"nctId":"NCT02091479","phase":"PHASE3","title":"Early Versus Late Resumption of Anticoagulation in Patients With Both High Thrombosis Risk and Major HEmoRrhage","status":"TERMINATED","sponsor":"Centre Hospitalier Universitaire de Saint Etienne","startDate":"2013-01","conditions":"Major hæmorrhage","enrollment":14},{"nctId":"NCT01356992","phase":"PHASE3","title":"Patients With High-risk Acute Coronary Syndrome Without ST-segment Elevation","status":"TERMINATED","sponsor":"Eurofarma Laboratorios S.A.","startDate":"2012-07","conditions":"Non ST Segment Elevation Myocardial Infarction, Unstable Angina","enrollment":62},{"nctId":"NCT00269880","phase":"PHASE3","title":"A Study Comparing the Efficacy and Safety of Abciximab, an Anti-Platelet Therapy, in Combination With Two Different Heparin Regimens in Patients Undergoing Percutaneous Coronary Intervention.","status":"COMPLETED","sponsor":"Centocor, Inc.","startDate":"1995-02","conditions":"Angioplasty, Transluminal, Percutaneous Coronary","enrollment":2792},{"nctId":"NCT01006876","phase":"PHASE3","title":"Role of Coumadin in Preventing Thromboembolism in Atrial Fibrillation (AF) Patients Undergoing Catheter Ablation","status":"COMPLETED","sponsor":"Texas Cardiac Arrhythmia Research Foundation","startDate":"2010-01","conditions":"Thromboembolism","enrollment":1584},{"nctId":"NCT00577096","phase":"NA","title":"Effects of Exercise in Combination With Epoetin Alfa","status":"COMPLETED","sponsor":"University of Arkansas","startDate":"2001-10","conditions":"Multiple Myeloma","enrollment":120},{"nctId":"NCT01433627","phase":"PHASE3","title":"Minimizing Adverse Haemorrhagic Events by TRansradial Access Site and Systemic Implementation of angioX","status":"UNKNOWN","sponsor":"Italian Society of Invasive Cardiology","startDate":"2011-10","conditions":"Acute Coronary Syndromes, STEMI, NSTEMI","enrollment":7200},{"nctId":"NCT00152971","phase":"PHASE3","title":"Dabigatran Etexilate vs Enoxaparin in Prevention of Venous Thromboembolism (VTE) Post Total Knee Replacement","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2004-11","conditions":"Arthroplasty, Replacement, Knee, Thromboembolism","enrollment":2615},{"nctId":"NCT00916669","phase":"PHASE2","title":"A Randomized Study to Evaluate the Effect of Two Different Doses of Enoxaparin Sodium in Combination With Standard Chemotherapy in Patients With Stage Small Cell Lung Cancer (SCLC)","status":"WITHDRAWN","sponsor":"Massachusetts General Hospital","startDate":"2008-07","conditions":"Small Cell Lung Cancer","enrollment":""},{"nctId":"NCT01634438","phase":"PHASE4","title":"Heparin Dose for Radial Angiography","status":"COMPLETED","sponsor":"University of Alberta","startDate":"2008-07","conditions":"Coronary Angiograph","enrollment":49},{"nctId":"NCT00435487","phase":"PHASE4","title":"Dalteparin Versus Unfractionated Heparin In Patients With Acute Coronary Syndrome","status":"TERMINATED","sponsor":"Pfizer","startDate":"2007-06","conditions":"Angina, Unstable, Myocardial Infarction","enrollment":173},{"nctId":"NCT00398463","phase":"PHASE4","title":"Study of Tirofiban Administration in Patients With Aspirin and or Clopidogrel Resistance","status":"COMPLETED","sponsor":"Università degli Studi di Ferrara","startDate":"2006-05","conditions":"Angioplasty, Transluminal, Percutaneous Coronary","enrollment":263},{"nctId":"NCT01168609","phase":"","title":"Left Atrial Distensibility and Left Ventricular Filling Pressure in Acute Myocardial Infarction","status":"COMPLETED","sponsor":"Kaohsiung Veterans General Hospital.","startDate":"2007-12","conditions":"Myocardial Infarction","enrollment":521},{"nctId":"NCT00917254","phase":"PHASE2, PHASE3","title":"Prevention of Venous Thromboembolism in Patients Undergoing Elective Total Knee Replacement Surgery","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2009-05","conditions":"Venous Thromboembolism","enrollment":369},{"nctId":"NCT00913120","phase":"PHASE2, PHASE3","title":"Prevention of Venous Thromboembolism in Patients Undergoing Elective Total Hip Replacement Surgery","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2009-05","conditions":"Venous Thromboembolism","enrollment":610},{"nctId":"NCT00790387","phase":"PHASE4","title":"Tirofiban and Enoxaparin in High Risk Coronary Intervention","status":"COMPLETED","sponsor":"The Prince Charles Hospital","startDate":"2004-06","conditions":"Acute Coronary Syndrome","enrollment":60},{"nctId":"NCT00133250","phase":"PHASE4","title":"Value of Abciximab in Patients With AMI Undergoing Primary PCI After Clopidogrel Pretreatment (BRAVE 3)","status":"COMPLETED","sponsor":"Deutsches Herzzentrum Muenchen","startDate":"2003-06","conditions":"Myocardial Infarction","enrollment":800},{"nctId":"NCT01063426","phase":"PHASE4","title":"Re-STOP DVT: Reload of High Dose Atorvastatin for Preventing Deep Vein Thrombosis in Statin Users","status":"UNKNOWN","sponsor":"Hallym University Medical Center","startDate":"2009-11","conditions":"Thrombosis, Prevention, Surgery","enrollment":180},{"nctId":"NCT00587444","phase":"PHASE3","title":"Optimal Heparin Dosing Regimens for Cardiopulmonary Bypass","status":"COMPLETED","sponsor":"Mayo Clinic","startDate":"2001-06","conditions":"Postoperative Hemorrhage","enrollment":270},{"nctId":"NCT00133003","phase":"PHASE4","title":"Abciximab, Clopidogrel and Percutaneous Coronary Intervention in Acute Coronary Syndrome (ISAR-REACT-2)","status":"COMPLETED","sponsor":"Deutsches Herzzentrum Muenchen","startDate":"2003-03","conditions":"Coronary Disease, Angina, Unstable","enrollment":2022},{"nctId":"NCT00611169","phase":"PHASE4","title":"The Effects of Facilitated Percutaeous Coronary Intervention in Acute Myocardial Infarction","status":"COMPLETED","sponsor":"Samsung Medical Center","startDate":"2006-01","conditions":"Acute Myocardial Infarction","enrollment":40}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":614,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"High dose of Unfractionated Heparin","genericName":"High dose of Unfractionated Heparin","companyName":"University of Patras","companyId":"university-of-patras","modality":"Small molecule","firstApprovalDate":"","aiSummary":"High-dose unfractionated heparin inhibits blood coagulation by potentiating antithrombin III, which inactivates thrombin and other clotting factors. Used for Acute coronary syndrome, Pulmonary embolism, Deep vein thrombosis.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}